Physician profile
Otis Barnum
NPI 1245224559
$2,966.94
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $185 · 2020: $220 · 2021: $221 · 2022: $1,743 · 2023: $368 · 2024: $230.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $598.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $598.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Research & Development, LLC | $1,373.62 | 2022 | |
| Novo Nordisk INC | $270.76 | 2020-2024 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $181.42 | 2019-2024 | |
| Paratek Pharmaceuticals, INC. | $165.90 | 2022-2024 | Nuzyra |
| Lilly USA, LLC | $131.21 | 2020-2024 | Mounjaro, Jardiance |
| Abbvie INC. | $128.14 | 2022-2024 | Vraylar, Ubrelvy |
| Glaxosmithkline, LLC. | $106.98 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $85.00 | 2021-2024 | |
| Amgen INC. | $75.97 | 2020-2024 | Repatha, Otezla |
| Allergan, INC. | $68.63 | 2019 | |
| Sanofi-Aventis U.S. LLC | $60.03 | 2020-2022 | |
| Abbott Laboratories | $56.40 | 2022 | |
| Evoke Pharma, INC. | $34.49 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.97 | 2023 | Xifaxan |
| Mylan Specialty L.P. | $24.28 | 2024 | Yupelri |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $23.80 | 2023 | Keveyis |
| Takeda Pharmaceuticals U.S.A., INC. | $18.10 | 2021 | |
| Eisai INC. | $17.77 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $17.28 | 2023 | Farxiga |
| Amarin Pharma, INC. | $16.87 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $16.67 | 2023 | Rexulti |
| Avanir Pharmaceuticals, INC. | $16.59 | 2021 | |
| Biogen, INC. | $16.35 | 2021 | |
| Astellas Pharma US INC | $13.64 | 2023 | Veozah |
| Kowa Pharmaceuticals America, INC. | $13.07 | 2022 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Otis Barnum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.